# Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

> **NCT01718379** · PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 132 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Epoetin beta

## Key facts

- **NCT ID:** NCT01718379
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-11
- **Final completion:** 2016-06
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2016-11-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01718379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01718379, "Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01718379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*